FDA Approves Striverdi Respimat , olodaterol to Treat Chronic Obstructive Pulmonary Disease
FDA Approves Striverdi Respimat , olodaterol to Treat Chronic Obstructive Pulmonary Disease
FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease
// // //
July 31, 2014 — Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction. Striverdi Respimat…
View On WordPress




